Key result
The CH-VAD demonstrated a 91.6% survival rate at 6-month and 1-year follow-ups in patients with end-stage heart failure, with no instances of pump thrombosis or device failure.
Why the study?
Clinical outcomes needed evaluation for the CH-VAD, a fully magnetically levitated left ventricular assist device designed for optimized hemocompatibility.
Does the CH-VAD provide reliable mechanical circulatory support and survival in patients with end-stage heart failure?
Observational (n=77)
Yes
Does the CH-VAD provide reliable mechanical circulatory support and survival in patients with end-stage heart failure?
The CH-VAD demonstrates excellent 1-year survival (91.6%) and a favorable safety profile with no pump thrombosis in Chinese patients with end-stage heart failure.
Supports CH-VAD evaluation in advanced HF; leaves open need for randomized trials versus established devices.
The CH-VAD is a fully magnetically levitated left ventricular assist device (LVAD) designed for optimized hemocompatibility. This study evaluates the clinical outcomes of 77 patients implanted with the CH-VAD across seven centers in China from June 2022 to June 2024. Patients had a mean age of 57.5 years, primarily classified as INTERMACS 2 or 3, with dilated and ischemic cardiomyopathy as the main causes of heart failure (HF). The study reported a 91.6% survival rate at both 6-month and 1-year follow-ups, aligning with international LVAD outcomes. Key adverse events were infrequent, including low rates of right HF, reoperation for bleeding, and driveline infection. Importantly, no pump thrombosis or device failures were noted. The results suggest that the CH-VAD is a reliable and effective long-term mechanical circulatory support option for end-stage HF patients in China, warranting further studies for long-term efficacy evaluation.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2025) conducted an observational in End-stage heart failure (n=77). CH-VAD was evaluated on Survival rate at 6-month and 1-year follow-ups. The CH-VAD demonstrated a 91.6% survival rate at 6-month and 1-year follow-ups in patients with end-stage heart failure, with no instances of pump thrombosis or device failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: